PETAH TIKVA, Israel, July 29, 2025 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announced today that its defense division, Gilat Defense, has been awarded a contract valued at over $8 million by Israel’s Ministry of Defense for the delivery and integration of satellite communication systems and services. Deliveries are expected in the next 12 months. The contract includes deployment of advanced SA ...

Semiconductor giant Qualcomm Inc. NASDAQ: QCOM is set to report earnings on Wednesday, and it couldn’t come at a more pivotal moment. The stock has been in a quiet but steady uptrend since April, gaining nearly 30% while flying under the radar compared to more explosive names like NVIDIA Corp NASDAQ: NVDA or Advanced Micro Devices Inc NASDAQ: AMD. QUALCOMM TodayQCOMQUALCOMM$161.05 +2.65 (+1.67%) 52-Week Range$120.80▼$182.64Dividend Yield2.21%P/E Ratio16.40Price Target$183.95Add to WatchlistTrading right ar ...

Advanced Micro Devices (NASDAQ: AMD), a rival to Nvidia (NASDAQ: NVDA), has received a bullish endorsement from BofA Securities, which maintained its ‘Buy’ rating and raised its price target from $175 to $200.The new target represents an increase of about 15% from AMD’s last closing price of $173. Notably, the semiconductor giant ended the previous session up over 4% and has rallied 11% over the past week.AMD one-week stock price chart. Source: FinboldThe price revision comes ahead of the company’s earnings ...

Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for the first six months of 2025 and updated full-year sales and operating profit outlook at CER. In the first six months of 2025, Novo Nordisk’s sales increased by 18% and operating profit increased by 29%, both at CER. Sales growth in the first six months of 2025 was positively impacted by gross-to-net sales adjustments related to prior years, including an adjustment related to ...

Group 1: Baker Hughes and Chart Industries Acquisition - Baker Hughes is nearing a $13.6 billion cash deal to acquire Chart Industries, valuing Chart at $210 per share, which represents a 22% premium over its Monday closing price [3] - This acquisition would replace an earlier agreement between Chart Industries and Flowserve, which had announced an all-stock merger valued at approximately $19 billion including debt [3] - The acquisition is expected to enhance Baker Hughes' presence in liquefied natural gas, nuclear energy, and data centers, thereby strengthening its industrial and energy technology division [4] Group 2: Cadence Design Systems - Cadence Design Systems has agreed to plead guilty to violating export laws and will pay over $140 million to the U.S. government for illegally selling semiconductor design technology to a Chinese military-associated entity [4][5] - The illegal sales occurred between 2015 and 2021, involving a front company linked to China's National University of Defense Technology, which was previously blacklisted by the U.S. Department of Commerce [5] Group 3: Warner Bros. Discovery - Warner Bros. Discovery has announced new names for its businesses, with the streaming and studios segment to be called "Warner Bros." and the networks segment to be named "Discovery Global" [6] - David Zaslav will serve as president and CEO of Warner Bros., while a chief financial officer for the business is yet to be appointed [7] - The networks business will encompass various entertainment, sports, and news television brands globally, including CNN and TNT Sports [7]

Group 1 - Apple is closing its store at Parkland Mall in Dalian City, marking the first store closure in China due to a changing retail landscape [2][3] - The company operates around 56 stores in the greater China region, which constitutes over 10% of its total global retail locations [2] - Apple reported a 2.3% decline in sales in China, totaling $16 billion in the second quarter, which was slightly below analyst expectations [4] Group 2 - China's overall smartphone market has seen a decline, with shipments dropping 4% to 69 million units in the second quarter after six consecutive quarters of growth [4] - Local competitors, particularly Huawei, have gained popularity, with Apple's iPhone ranking fifth in the market, although the company has managed to narrow its decline [5] - The pressures faced by Apple in China are part of a broader crisis as competitors advance in the artificial intelligence sector [5][7]

Core Viewpoint - Johnson Controls International plc reported strong fiscal third quarter 2025 results, with a notable increase in sales and adjusted earnings per share, reflecting the company's focus on innovation and customer commitment [2][3][7]. Financial Performance - The company achieved GAAP earnings per share (EPS) of $0.94 and adjusted EPS of $1.05 for the third quarter [2]. - Total sales for the quarter reached $6.1 billion, marking a 3% increase year-over-year, with organic sales growth of 6% [2][7]. - GAAP income from continuing operations was $618 million, while adjusted income from continuing operations was $693 million [2]. Segment Results - **Americas**: Sales remained flat at $4.0 billion, with organic sales increasing by 7%. GAAP segment EBITA was $742 million, down 8% year-over-year [5][6]. - **EMEA**: Sales increased by 8% to $1.3 billion, with a 15% rise in GAAP segment EBITA [8][9]. - **APAC**: Sales grew by 7% to $737 million, with a 12% increase in GAAP segment EBITA [9][10]. Orders and Backlog - Excluding M&A and adjusted for foreign currency, orders increased by 5% year-over-year, and the backlog reached $10.3 billion, up 10% year-over-year [6][7]. Cash Flow and Shareholder Returns - Cash provided by operating activities was $787 million, with free cash flow of $693 million and adjusted free cash flow of $725 million [12][39]. - The company paid dividends totaling $243 million and repurchased 3.8 million shares for $310 million [12]. Guidance - The company raised its full-year fiscal 2025 guidance, projecting organic sales growth of mid-single digits and adjusted EPS of $3.65 to $3.68 [19][14].

格隆汇7月28日丨复旦微电(688385.SH)公布，公司拟与复旦大学签署《技术服务合同》，委托复旦大学 研究开发超大规模FPGA布局布线技术并提供相应的技术支持，合同金额350万元人民币。本合同经公 司董事会审议通过后，与复旦大学签署生效。 ...

Core Insights - Fulcrum Therapeutics reported promising results from the 12 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease (SCD), showing a robust mean increase of 8.6% in fetal hemoglobin (HbF) and improvements in key markers of hemolysis and anemia [1][5] - The company ended Q2 2025 with $214.1 million in cash, providing a cash runway into 2028 [1][6] - Collaboration revenue was zero for Q2 2025, a decrease from $80 million in Q2 2024, primarily due to the recognition of an upfront license payment from Sanofi in the previous year [5][11] Recent Business Highlights - The 12 mg dose cohort of the PIONEER trial demonstrated no treatment-related serious adverse events, indicating that pociredir was generally well-tolerated [1][5] - The ongoing 20 mg dose cohort is expected to provide clinical data by the end of 2025 [1][5] - Fulcrum is advancing its program for inherited aplastic anemias and plans to submit an investigational new drug application for Diamond-Blackfan anemia in Q4 2025 [5] Financial Results - Research and development expenses for Q2 2025 were $13 million, down from $17.3 million in Q2 2024, attributed to reduced employee compensation costs and the discontinuation of the losmapimod program [5][11] - General and administrative expenses decreased to $6.8 million in Q2 2025 from $10.2 million in Q2 2024, reflecting lower professional services and employee compensation costs [11] - The net loss for Q2 2025 was $17.3 million, compared to a net income of $55.4 million in Q2 2024 [11][16]

Core Insights - Fulcrum Therapeutics reported positive results from the 12 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease (SCD) [2][3] Efficacy Data - The mean absolute fetal hemoglobin (HbF) increased by 8.6% from a baseline of 7.6% to 16.2% after 12 weeks of treatment, with 7 out of 16 patients achieving HbF levels greater than 20% [4][10] - The proportion of F-cells increased from 34% at baseline to 67% at 12 weeks, indicating pan-cellular induction of HbF [4][10] - Key markers of hemolysis showed meaningful improvements, including a mean increase in total hemoglobin of 0.9 g/dL, from 7.8 g/dL to 8.7 g/dL [10] - A trend of reduced vaso-occlusive crisis (VOC) rates was observed, with 50% of patients reporting no VOCs during the treatment period [10] Safety Profile - Pociredir was generally well-tolerated, with no treatment-related serious adverse events (SAEs) reported, and all treatment-related adverse events (AEs) were Grade 1 [3][10] - The safety profile observed in the 12 mg dose cohort was consistent with previously reported data [10] Company Overview - Fulcrum Therapeutics is focused on developing small molecules for genetically defined rare diseases, with pociredir as its lead clinical program aimed at increasing HbF expression for SCD treatment [8][9]